The New Republic on MSN5 小时
How Big Pharma Is Wrecking the Inflation Reduction Act
The industry’s intellectual property manipulations are stealing from your pockets—and limiting the benefits of the Biden ...
Mankind Pharma, Innovent Biologics partner to bring immunotherapy drug sintilimab to India
Mankind Pharma partners with Innovent Biologics to bring advanced immunotherapy drug, sintilimab, to Indian market ...
Pharma company spends ₹1.91 crore on foreign travel of doctors, gets reprimanded
AbbVie Healthcare India Pvt. Ltd. found breaching UCPMP by sponsoring international trips for doctors, facing reprimand and ...
Akums inks €200 million agreement with a global pharma company for the European market
Akums Group secures €200 million deal to manufacture formulations for European market, expanding global footprint and ...
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
To navigate this increasingly complex environment in 2025, pharma manufacturers must fundamentally rethink their models and ...
The Financial Express2 天
Indian pharma companies focus on innovative research in foreign countries through dedicated ...
Historically, leading Indian players like Sun Pharma and Dr. Reddy’s used to execute their innovative R&D in India through a ...
Mankind Pharma inks pact with Innovent for immunotherapy drug in India
Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and ...
Verona Pharma股价飙升至历史新高43.76美元
在市场信心的显著表现下，Verona Pharma的股价已飙升至历史新高，达到43.76美元的价格水平。根据 InvestingPro ...
manilatimes16 小时
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 - ...
McKinsey & Company agrees to pay $650M for helping Purdue Pharma boost opioid sales
McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids ...
MEI Pharma股价触及52周低点2.54美元，面临市场挑战
在充满挑战的市场环境中，MEI Pharma Inc (NASDAQ: MEIP)股价触及52周低点，达到2.54美元的价格水平。该公司市值仅为1766万美元，但保持着强劲的流动性状况，其流动比率为9.66。根据 InvestingPro 的分析，公司的整体财务健康评分为"一般"。这一下跌反映了公司股价相比去年的显著收缩，一年内变化率为-58.14%。投资者正密切关注MEI ...